Lymphoma Therapy

Lymphocyte dose correlated with survival after auto-SCT in NHL patients

Published in Blood Weekly, March 25th, 2004

Lymphocyte dose is strongly correlated with survival in non-Hodgkin lymphoma (NHL) patients treated with stem-cell autografts.

"Absolute lymphocyte count at day 15 (ALC-15) after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT) is an independent prognostic factor for survival" in NHL, scientists in the United States explained. However, "factors affecting ALC-15 remain unknown."

In a recent study, L.F. Porrata and colleagues at the Mayo Clinic tested their hypothesis that "dose of infused autograft lymphocytes (A-ALC) directly impacts upon ALC-15."

"A total of 190 consecutive NHL patients received A-ALC...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-03-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry